CoChat

Oculopharyngeal muscular dystrophy (OPMD) associated alanine expansion impairs the function of the nuclear polyadenosine RNA binding protein PABPN1 as revealed by proximity labeling and comparative proteomics

Open access

Published version of a preprint

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; none of the 76 sources its claims cite is checked for support yet.

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset disease caused by modest alanine expansion at the amino terminus of the nuclear polyadenosine RNA binding protein PABPN1. PABPN1 is expressed ubiquitously and is involved in multiple steps in RNA processing including optimal cleavage and polyadenylation, polyadenylation signal selection, and export of polyadenylated RNAs from the nucleus. Expanded PABPN1 forms aggregates in a subset of muscle nuclei, but PABPN1 levels are paradoxically low in muscle compared to other tissues. Despite several studies in model systems and patient tissues, it remains unclear whether alanine expansion directly impairs PABPN1 function. The molecular mechanisms leading to OPMD pathology are poorly understood. Here we used a proximity labeling approach to better understand the effect of alanine expansion on PABPN1 function in a cell culture model of skeletal muscle. To avoid the confounding factor of overexpression, PABPN1 constructs containing a carboxy-terminal TurboID tag were expressed in skeletal myotubes at near native levels using an inducible promoter. Although non-expanded PABPN1-TurboID was able to complement RNA export and myoblast differentiation defects caused by deficiency of endogenous PABPN1, alanine expanded PABPN1-TurboID was not. Comparative proteomics revealed increased interaction between expanded PABPN1 and RNA splicing and polyadenylation machinery and follow-up studies identified a dominant negative effect of expanded PABPN1 on RNA export in differentiated myotubes. These data indicate that alanine expansion can impair PABPN1 function regardless of the presence of wild type PABPN1 and support a model wherein both loss function and dominant negative effects of expanded PABPN1 contribute to OPMD pathology.

Overview

CoChat Summary

TL;DR

Alanine-expanded PABPN1 (Ala17) expressed at near-native levels in C2C12 myotubes fails to fully complement PABPN1 loss and exerts dominant negative effects on RNA export and differentiation. Proximity labeling and comparative proteomics show Ala17 PABPN1 has increased interactions with splicing/polyadenylation and ubiquitin-proteasome proteins, reduced stability, and reduced interaction with nuclear export machinery.

Key findings

  • Ala10 PABPN1-TurboID reversed nuclear poly(A) RNA accumulation and restored myotube fusion in Pabpn1 knockdown cells, whereas Ala17 PABPN1-TurboID did not fully rescue these phenotypes; both rescued the reduced nuclei/survival phenotype.
  • Ala17 PABPN1-TurboID caused a dominant negative effect: reduced fusion index in control myotubes, increased nuclear poly(A) RNA accumulation at near-native and overexpression levels, and nuclear accumulation of the Tnnt3 transcript; primary myotubes from Pabpn1+/A17 mice also showed reduced cytoplasmic poly(A) RNA signal.
  • Proteomics identified 595 proteins at FDR ≥95%; 130 proteins in Ala10 and 142 in Ala17 PABPN1-TurboID eluates, with 6 unique to Ala10 and 18 unique to Ala17. Ala17-enriched proteins included RNA splicing/polyadenylation and ubiquitin-proteasome components, e.g., NUDT21 fold change 2.24, ZC3H14 2.08, UBE2D3 2.64, while NUP214 was lower in Ala17.
  • Cycloheximide chase showed half-lives of ~10 h for endogenous PABPN1, ~15 h for Ala10 PABPN1-TurboID, and ~2 h for Ala17 PABPN1-TurboID; endogenous PABPN1 half-life was reduced in Ala17-expressing cells, and Ala17 showed reduced interaction with THOC5.

Methods

  • Stable C2C12 myoblast lines expressing doxycycline-inducible Ala10 or Ala17 PABPN1-TurboID were differentiated into myotubes and induced to near-native levels (~50% of endogenous PABPN1), then treated with biotin for proximity labeling.
  • Functional assays included Pabpn1 siRNA knockdown/rescue, immunofluorescence, oligo d(T) FISH, subcellular fractionation, qPCR of fractionated myotubes, cycloheximide chase, streptavidin precipitation, and THOC5 co-immunoprecipitation.
  • Comparative proteomics used label-free nanoLC-MS/MS on streptavidin-captured biotinylated proteins from three independent experiments, with strict filtering (detected in ≥2/3 replicates and not in wild type) and STRING functional annotation.

Limitations

  • Stated: the use of C2C12 myotubes is a limitation; some PABPN1 functions, such as DNA double-strand break repair, were not represented, and effects may differ by differentiation state and muscle group.
  • Stated: proteomics cannot distinguish Ala10 PABPN1-TurboID sequence from endogenous PABPN1, and no PABPN1 aggregates were detected in myotubes, possibly because expanded PABPN1 was expressed for only 48 hours.
  • Evident from the text: near-native expression was defined as ~50% of endogenous PABPN1 rather than exactly one allele; the C-terminal TurboID tag led to some additional cytosolic PABPN1-TurboID signal; strict proteomics cutoffs may miss low-abundance or transient interactors.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1011743

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Ala10 and Ala17 PABPN1-TurboID constructs can be induced to express at near-native levels. A) Schematic outlining the experimental approach to express Ala10 and Ala17 PABPN1-TurboID in differentiated C2C12 myotubes. Genes encoding PABPN1-TurboID constructs containing Flag tag (FL) and Myc tag were cloned into the pCW57.1 lentiviral vector under the control of a tetracycline responsive element (TRE). C2C12 myoblasts were transduced and allowed to differentiate to myotubes. Lysates from doxycycline-treated myotubes were assayed by immunoblots shown and quantified in B-D. In all cases, Ponceau staining was used as a loading control. B) PABPN1-TurboID constructs detected as a band just below 100 kDa using an antibody to BirA, the parent protein of engineered TurboID. C) PABPN1-TurboID constructs (top band) as detected by antibody to PABPN1 (top blot) allowing for comparison to endogenous PABPN1 (bottom band) and detection of dose-dependent biotinylation using streptavidin conjugated to horseradish peroxidase (HRP, middle blot). D) Ratio of PABPN1-TurboID constructs to endogenous PABPN1 showing that PABPN1-TurboID can be expressed at near-native levels (~50 of endogenous PABPN1). Shown are individual measurements and mean ± standard deviation for n = 3 experiments. E) Confirmation of expression of Ala17 PABPN1-TurboID as detected by an antibody to alanine expansion and of proximal protein biotinylation as detected by streptavidin-HRP in streptavidin capture eluates from doxycycline-treated myotubes. Shown is a blot from one representative elution with additional replicates shown in S1E Fig. Wild type (WT) C2C12 myotubes were used as a control for endogenous biotin-binding proteins.
Fig 1 Ala10 and Ala17 PABPN1-TurboID constructs can be induced to express at near-native levels. A) Schematic outlining the experimental approach to express Ala10 and Ala17 PABPN1-TurboID in differentiated C2C12 myotubes. Genes encoding PABPN1-TurboID constructs containing Flag tag (FL) and Myc tag were cloned into the pCW57.1 lentiviral vector under the control of a tetracycline responsive element (TRE). C2C12 myoblasts were transduced and allowed to differentiate to myotubes. Lysates from doxycycline-treated myotubes were assayed by immunoblots shown and quantified in B-D. In all cases, Ponceau staining was used as a loading control. B) PABPN1-TurboID constructs detected as a band just below 100 kDa using an antibody to BirA, the parent protein of engineered TurboID. C) PABPN1-TurboID constructs (top band) as detected by antibody to PABPN1 (top blot) allowing for comparison to endogenous PABPN1 (bottom band) and detection of dose-dependent biotinylation using streptavidin conjugated to horseradish peroxidase (HRP, middle blot). D) Ratio of PABPN1-TurboID constructs to endogenous PABPN1 showing that PABPN1-TurboID can be expressed at near-native levels (~50 of endogenous PABPN1). Shown are individual measurements and mean ± standard deviation for n = 3 experiments. E) Confirmation of expression of Ala17 PABPN1-TurboID as detected by an antibody to alanine expansion and of proximal protein biotinylation as detected by streptavidin-HRP in streptavidin capture eluates from doxycycline-treated myotubes. Shown is a blot from one representative elution with additional replicates shown in S1E Fig. Wild type (WT) C2C12 myotubes were used as a control for endogenous biotin-binding proteins.CC BY · PubMed Central
Fig 2 Ala10 and Ala17 PABPN1-TurboID constructs localize to the nucleus and cytoplasm in myotubes. A) Sub-cellular fractionation of myotube lysates derived from WT or stable cells expressing Ala10 and Ala17 PABPN1-TurboID analyzed by immunoblot using antibodies to PABPN1 and BirA. GAPDH and Histone-H3 serve as controls for cytoplasmic and nuclear fractions, respectively. Ponceau staining was used as a loading control. B) Quantification of cytoplasmic/nuclear ratio of PABPN1-TurboID constructs as detected by antibody to PABPN1 shown in A. Shown is mean ± standard deviation for n = 5-6 experiments. Statistical calculations used unpaired t-test. C) Quantification of cytoplasmic/nuclear ratio of endogenous PABPN1 as detected by antibody to PABPN1 shown in A. Shown is mean ± standard deviation for n = 6 experiments. Statistical calculation used ordinary one-way ANOVA. D) Immunostaining with an antibody to PABPN1 (green) in myotubes from WT and stable cells expressing near-native levels of Ala10 and Ala17 PABPN1-TurboID. Immunostaining with an antibody to embryonic myosin heavy chain (red) was used to detect myotubes. Gray scale insets show PABPN1 staining in isolation. Bar = 100 µm. E) Staining using Alexa Fluor 488-conjugated streptavidin (Streptavidin-488, green) to detect biotin and an antibody to PABPN1 (red) to detect total PABPN1. Gray scale insets show Alexa Fluor-488 streptavidin staining in isolation. Bar = 100 µm. For D and E, shown are representative images with additional replicates shown in S2 Fig.
Fig 2 Ala10 and Ala17 PABPN1-TurboID constructs localize to the nucleus and cytoplasm in myotubes. A) Sub-cellular fractionation of myotube lysates derived from WT or stable cells expressing Ala10 and Ala17 PABPN1-TurboID analyzed by immunoblot using antibodies to PABPN1 and BirA. GAPDH and Histone-H3 serve as controls for cytoplasmic and nuclear fractions, respectively. Ponceau staining was used as a loading control. B) Quantification of cytoplasmic/nuclear ratio of PABPN1-TurboID constructs as detected by antibody to PABPN1 shown in A. Shown is mean ± standard deviation for n = 5-6 experiments. Statistical calculations used unpaired t-test. C) Quantification of cytoplasmic/nuclear ratio of endogenous PABPN1 as detected by antibody to PABPN1 shown in A. Shown is mean ± standard deviation for n = 6 experiments. Statistical calculation used ordinary one-way ANOVA. D) Immunostaining with an antibody to PABPN1 (green) in myotubes from WT and stable cells expressing near-native levels of Ala10 and Ala17 PABPN1-TurboID. Immunostaining with an antibody to embryonic myosin heavy chain (red) was used to detect myotubes. Gray scale insets show PABPN1 staining in isolation. Bar = 100 µm. E) Staining using Alexa Fluor 488-conjugated streptavidin (Streptavidin-488, green) to detect biotin and an antibody to PABPN1 (red) to detect total PABPN1. Gray scale insets show Alexa Fluor-488 streptavidin staining in isolation. Bar = 100 µm. For D and E, shown are representative images with additional replicates shown in S2 Fig.CC BY · PubMed Central
Fig 3 Ala10 PABPN1-TurboID functionally complements endogenous PABPN1 deficiency while Ala17 PABPN1-TurboID only partially rescues PABPN1 loss. A) Fluorescence in situ hybridization (FISH) in myoblasts with (siPabpn1) and without (siScr) Pabpn1 knockdown using d(T)30-AF488 to detect polyadenylated RNA with immunostaining using an antibody to PABPN1 to show knockdown. FISH was performed in wild type (WT) cells or stable cells expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID. Top row: insets show d(T)30-AF488 in gray scale. Bottom row: insets show PABPN1 staining in gray scale. Bar = 100 µm. Shown are representative images with additional replicates shown in S3 Fig. B) Quantification of total nuclei in control (siScr) and knockdown (siPabpn1) myoblasts from A showing decreased cell count in siScr myoblasts expressing Ala17 PABPN1-TurboID. Shown is mean ± standard deviation for n = 3 experiments. Statistical significance was determined by one-way ANOVA. ** p < 0.01. C) Immunoblot probed with antibody to BirA (PABPN1-TurboID) or PABPN1 showing PABPN1 knockdown and replacement with Ala10 PABPN1-TurboID in myoblasts induced to differentiate in the presence of Pabpn1 targeting siRNA (siPab) with or without co-transfection with plasmid encoding Ala10 PABPN1-TurboID. Ponceau staining was used as a loading control. D) Immunostaining using an antibody to embryonic myosin heavy chain (eMyHC) to visualize myotubes in cells with (siPab) and without (siScr) Pabpn1 knockdown or expression of Ala10 PABPN1-TurboID. DAPI staining used to visualize nuclei. Shown are representative images. E) Fusion index calculated for Pabpn1 knockdown myotubes (siPab) showing rescue of differentiation upon expression of Ala10 PABPN1-TurboID (+Ala10) in Pabpn1 knockdown myotubes. Shown is mean ± standard deviation for n = 4 experiments. Statistical significance determined by one-way ANOVA. * p < 0.05. F) Immunoblot showing Pabpn1 knockdown and replacement with Ala17 PABPN1-TurboID similar to experiment shown in C. G) Immunostaining using eMyHC antibody in Pabpn1 knockdown and replacement with Ala17 PABPN1-TurboID similar to experiment shown in D. H) Fusion index similar to that shown in E showing only partial rescue of differentiation upon expression of Ala17 PABPN1-TurboID in Pabpn1 knockdown myotubes. Shown is mean ± standard deviation for n = 4 experiments. Statistical significance determined by one-way ANOVA. * p < 0.05. I) Fusion index calculated for control myotubes (nontreated or siScr) expressing Ala10 or Ala17 PABPN1-TurboID showing dominant negative effect of Ala17 on fusion index. Shown are n = 8 replicates for each experiment. Statistical significance determined by two-way ANOVA. * p < 0.05. J) Total nuclei as a measurement of survival showing reduced nuclear count in Pabpn1 knockdown myotubes (siPab) that is fully rescued upon expression of Ala10 or Ala17 PABPN1-TurboID. Shown is mean ± standard deviation for n = 4-8 experiments. Statistical significance determined by one-way ANOVA. ** p < 0.01.
Fig 3 Ala10 PABPN1-TurboID functionally complements endogenous PABPN1 deficiency while Ala17 PABPN1-TurboID only partially rescues PABPN1 loss. A) Fluorescence in situ hybridization (FISH) in myoblasts with (siPabpn1) and without (siScr) Pabpn1 knockdown using d(T)30-AF488 to detect polyadenylated RNA with immunostaining using an antibody to PABPN1 to show knockdown. FISH was performed in wild type (WT) cells or stable cells expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID. Top row: insets show d(T)30-AF488 in gray scale. Bottom row: insets show PABPN1 staining in gray scale. Bar = 100 µm. Shown are representative images with additional replicates shown in S3 Fig. B) Quantification of total nuclei in control (siScr) and knockdown (siPabpn1) myoblasts from A showing decreased cell count in siScr myoblasts expressing Ala17 PABPN1-TurboID. Shown is mean ± standard deviation for n = 3 experiments. Statistical significance was determined by one-way ANOVA. ** p < 0.01. C) Immunoblot probed with antibody to BirA (PABPN1-TurboID) or PABPN1 showing PABPN1 knockdown and replacement with Ala10 PABPN1-TurboID in myoblasts induced to differentiate in the presence of Pabpn1 targeting siRNA (siPab) with or without co-transfection with plasmid encoding Ala10 PABPN1-TurboID. Ponceau staining was used as a loading control. D) Immunostaining using an antibody to embryonic myosin heavy chain (eMyHC) to visualize myotubes in cells with (siPab) and without (siScr) Pabpn1 knockdown or expression of Ala10 PABPN1-TurboID. DAPI staining used to visualize nuclei. Shown are representative images. E) Fusion index calculated for Pabpn1 knockdown myotubes (siPab) showing rescue of differentiation upon expression of Ala10 PABPN1-TurboID (+Ala10) in Pabpn1 knockdown myotubes. Shown is mean ± standard deviation for n = 4 experiments. Statistical significance determined by one-way ANOVA. * p < 0.05. F) Immunoblot showing Pabpn1 knockdown and replacement with Ala17 PABPN1-TurboID similar to experiment shown in C. G) Immunostaining using eMyHC antibody in Pabpn1 knockdown and replacement with Ala17 PABPN1-TurboID similar to experiment shown in D. H) Fusion index similar to that shown in E showing only partial rescue of differentiation upon expression of Ala17 PABPN1-TurboID in Pabpn1 knockdown myotubes. Shown is mean ± standard deviation for n = 4 experiments. Statistical significance determined by one-way ANOVA. * p < 0.05. I) Fusion index calculated for control myotubes (nontreated or siScr) expressing Ala10 or Ala17 PABPN1-TurboID showing dominant negative effect of Ala17 on fusion index. Shown are n = 8 replicates for each experiment. Statistical significance determined by two-way ANOVA. * p < 0.05. J) Total nuclei as a measurement of survival showing reduced nuclear count in Pabpn1 knockdown myotubes (siPab) that is fully rescued upon expression of Ala10 or Ala17 PABPN1-TurboID. Shown is mean ± standard deviation for n = 4-8 experiments. Statistical significance determined by one-way ANOVA. ** p < 0.01.CC BY · PubMed Central
Fig 4 Proteomic analysis detects similar Ala10 and Ala17 PABPN1 proximal proteins. A) Experimental design included three individual replicates each of wild type (WT) myotubes or myotubes expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID. B) Proximal proteins detected in all three Ala10 or Ala17 PABPN1 replicates but not in WT samples revealed similar numbers of putative interacting proteins for both constructs and 6 and 18 being unique to Ala10 and Ala17 PABPN1-TurboID, respectively. C) Proteins detected in Ala10 PABPN1-TurboID eluates that did not meet cutoff criteria (2/3 replicates, not detected in WT) for Ala17 PABPN1-TurboID and those detected in Ala17 PABPN1-TurboID that did not meet the cutoff criteria for Ala10 PABPN1-TurboID. D) Gene ontology analysis showing similar molecular functions of Ala10 and Ala17 PABPN1-TurboID proximal proteins. E) Gene ontology analysis showing molecular function of Ala17 PABPN1 enriched proximal proteins were mostly related to RNA metabolism and RNA splicing. F) Proteins related to splicing, polyadenylation, RNA decay, and ubiquitylation enriched in Ala17 PABPN1 proximal proteins. Starred (*) proteins met cutoff criteria only in Ala17 PABPN1-TurboID eluates. Additional functional annotation shown in S5 Fig.
Fig 4 Proteomic analysis detects similar Ala10 and Ala17 PABPN1 proximal proteins. A) Experimental design included three individual replicates each of wild type (WT) myotubes or myotubes expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID. B) Proximal proteins detected in all three Ala10 or Ala17 PABPN1 replicates but not in WT samples revealed similar numbers of putative interacting proteins for both constructs and 6 and 18 being unique to Ala10 and Ala17 PABPN1-TurboID, respectively. C) Proteins detected in Ala10 PABPN1-TurboID eluates that did not meet cutoff criteria (2/3 replicates, not detected in WT) for Ala17 PABPN1-TurboID and those detected in Ala17 PABPN1-TurboID that did not meet the cutoff criteria for Ala10 PABPN1-TurboID. D) Gene ontology analysis showing similar molecular functions of Ala10 and Ala17 PABPN1-TurboID proximal proteins. E) Gene ontology analysis showing molecular function of Ala17 PABPN1 enriched proximal proteins were mostly related to RNA metabolism and RNA splicing. F) Proteins related to splicing, polyadenylation, RNA decay, and ubiquitylation enriched in Ala17 PABPN1 proximal proteins. Starred (*) proteins met cutoff criteria only in Ala17 PABPN1-TurboID eluates. Additional functional annotation shown in S5 Fig.CC BY · PubMed Central
Fig 5 Reduced half-life of soluble and insoluble Ala17 PABPN1-TurboID compared to Ala10 PABPN1-TurboID and endogenous PABPN1. A) Immunoblot of cycloheximide (CHX) chase experiments showing similar stability of Ala10 PABPN1-TurboID and endogenous PABPN1 as detected by an antibody to PABPN1 in myotubes expressing near native levels of Ala10 PABPN1-TurboID. B) Immunoblot of cycloheximide chase experiments showing stability of endogenous PABPN1 in wild type cells. C) Immunoblot of cycloheximide chase experiments showing relative instability of Ala17 PABPN1-TurboID in myotubes expressing near native levels of Ala17 PABPN1-TurboID with little effect on endogenous PABPN1 stability using an antibody to PABPN1. For A-C, Ponceau stain was used as a loading control. D) Non-linear fit and one-phase decay calculation showing reduced half-life of Ala17 PABPN1-TurboID relative to Ala10 PABPN1-TurboID and endogenous PABPN1. Shown is mean ± standard deviation for n = 3-5 experiments. Statistical significance was determined by mixed-effects analysis with Tukey’s post-hoc test. p < 0.05 for comparison of Ala10 PABPN1-TurboID to endogenous PABPN1. p < 0.01 for comparison between Ala17 PABPN1-TurboID and endogenous PABPN1. p < 0.0001 for comparison between Ala17 and Ala10 PABPN1-TurboID. E) Non-linear fit and one-phase decay calculation showing reduced half-life of endogenous PABPN1 in cells expressing Ala17 PABPN1-TurboID relative to cells expressing Ala10 PABPN1-TurboID. Shown is mean ± standard deviation for n = 3 experiments. Statistical significance was determined as in (D). F) Immunoblot of insoluble fractions from cycloheximide chase experiment showing presence of Ala17 PABPN1-TurboID and endogenous PABPN1 in myotubes expressing Ala17 PABPN1-TurboID as detected using an antibody to PABPN1. Reduced stability of both Ala17 PABPN1-TurboID and endogenous PABPN1 can be observed relative to PABPN1 in the soluble fractions shown in A-C. G) Immunoblot of myotubes without cycloheximide showing increased presence of PABPN1-TurboID, endogenous PABPN1, and TDP-43 in the insoluble fraction in myotubes expressing Ala17 PABPN1. Ponceau stain was used as a loading control. H) Immunoblot of insoluble fractions from cycloheximide chase experiment showing little to no Ala10 PABPN1-TurboID or endogenous PABPN1 in myotubes expressing Ala10 PABPN1-TurboID. For E and H, stain-free gel imaging used as a loading control.
Fig 5 Reduced half-life of soluble and insoluble Ala17 PABPN1-TurboID compared to Ala10 PABPN1-TurboID and endogenous PABPN1. A) Immunoblot of cycloheximide (CHX) chase experiments showing similar stability of Ala10 PABPN1-TurboID and endogenous PABPN1 as detected by an antibody to PABPN1 in myotubes expressing near native levels of Ala10 PABPN1-TurboID. B) Immunoblot of cycloheximide chase experiments showing stability of endogenous PABPN1 in wild type cells. C) Immunoblot of cycloheximide chase experiments showing relative instability of Ala17 PABPN1-TurboID in myotubes expressing near native levels of Ala17 PABPN1-TurboID with little effect on endogenous PABPN1 stability using an antibody to PABPN1. For A-C, Ponceau stain was used as a loading control. D) Non-linear fit and one-phase decay calculation showing reduced half-life of Ala17 PABPN1-TurboID relative to Ala10 PABPN1-TurboID and endogenous PABPN1. Shown is mean ± standard deviation for n = 3-5 experiments. Statistical significance was determined by mixed-effects analysis with Tukey’s post-hoc test. p < 0.05 for comparison of Ala10 PABPN1-TurboID to endogenous PABPN1. p < 0.01 for comparison between Ala17 PABPN1-TurboID and endogenous PABPN1. p < 0.0001 for comparison between Ala17 and Ala10 PABPN1-TurboID. E) Non-linear fit and one-phase decay calculation showing reduced half-life of endogenous PABPN1 in cells expressing Ala17 PABPN1-TurboID relative to cells expressing Ala10 PABPN1-TurboID. Shown is mean ± standard deviation for n = 3 experiments. Statistical significance was determined as in (D). F) Immunoblot of insoluble fractions from cycloheximide chase experiment showing presence of Ala17 PABPN1-TurboID and endogenous PABPN1 in myotubes expressing Ala17 PABPN1-TurboID as detected using an antibody to PABPN1. Reduced stability of both Ala17 PABPN1-TurboID and endogenous PABPN1 can be observed relative to PABPN1 in the soluble fractions shown in A-C. G) Immunoblot of myotubes without cycloheximide showing increased presence of PABPN1-TurboID, endogenous PABPN1, and TDP-43 in the insoluble fraction in myotubes expressing Ala17 PABPN1. Ponceau stain was used as a loading control. H) Immunoblot of insoluble fractions from cycloheximide chase experiment showing little to no Ala10 PABPN1-TurboID or endogenous PABPN1 in myotubes expressing Ala10 PABPN1-TurboID. For E and H, stain-free gel imaging used as a loading control.CC BY · PubMed Central
Fig 6 Components of the RNA export machinery pathway are labeled less by Ala17 PABPN1-TurboID. A) Immunoblots probed with antibodies to various components of TREX complex (ALYREF, THOC1, THOC2, THOC5) comparing levels in myotubes compared to myoblasts. Blots were probed with antibody to PABPN1 as a positive control for reduced levels of RNA processing machinery in myotubes and an antibody to myosin heavy chain (eMyHC) as a marker of differentiation. Ponceau stain was used as a loading control. B) Quantification of blots shown in A showing significantly reduced levels of THOC1, THOC5, and PABPN1 in myotubes compared to myoblasts. Shown is mean ± standard deviation for n = 4 experiments. C) Immunoblot of streptavidin elutions from myotubes expressing Ala10 or Ala17 PABPN1-TurboID probed with antibodies to nuclear export proteins THOC5 and ALYREF. TDP-43 used as a positive control for increased interaction with Ala17 PABPN1. HuR was used as a negative control. D) Quantification of experiments represented in C. Shown is mean ± standard deviation for n = 3 experiments. E) Immunoblot of precipitation using antibody to THOC5 probed with anti-BirA antibody to detect PABPN1-TurboID. An antibody to ALYREF was used as a positive control. Beads loaded with non-specific rabbit IgG (RIgG) and eluates probed with an antibody to HuR were used as negative controls. F) Quantification of BirA bands from blot shown in E. For B and D statistical significance was determined using two-way ANOVA with Šídák’s multiple comparisons test. * p < 0.05, ** p < 0.01.
Fig 6 Components of the RNA export machinery pathway are labeled less by Ala17 PABPN1-TurboID. A) Immunoblots probed with antibodies to various components of TREX complex (ALYREF, THOC1, THOC2, THOC5) comparing levels in myotubes compared to myoblasts. Blots were probed with antibody to PABPN1 as a positive control for reduced levels of RNA processing machinery in myotubes and an antibody to myosin heavy chain (eMyHC) as a marker of differentiation. Ponceau stain was used as a loading control. B) Quantification of blots shown in A showing significantly reduced levels of THOC1, THOC5, and PABPN1 in myotubes compared to myoblasts. Shown is mean ± standard deviation for n = 4 experiments. C) Immunoblot of streptavidin elutions from myotubes expressing Ala10 or Ala17 PABPN1-TurboID probed with antibodies to nuclear export proteins THOC5 and ALYREF. TDP-43 used as a positive control for increased interaction with Ala17 PABPN1. HuR was used as a negative control. D) Quantification of experiments represented in C. Shown is mean ± standard deviation for n = 3 experiments. E) Immunoblot of precipitation using antibody to THOC5 probed with anti-BirA antibody to detect PABPN1-TurboID. An antibody to ALYREF was used as a positive control. Beads loaded with non-specific rabbit IgG (RIgG) and eluates probed with an antibody to HuR were used as negative controls. F) Quantification of BirA bands from blot shown in E. For B and D statistical significance was determined using two-way ANOVA with Šídák’s multiple comparisons test. * p < 0.05, ** p < 0.01.CC BY · PubMed Central
Fig 7 Ala17 PABPN1 causes a dominant negative effect on polyadenylated RNA localization. A) Fluorescence in situ hybridization (FISH) in wild type (WT) myotubes or myotubes expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID using d(T)30-AF-488 to detect polyadenylated RNA and DAPI to stain nuclei. Representative images are shown at low (top) and high (bottom) magnification. Red arrows mark polyadenylated RNA puncta. Gray scale insets show d(T)30-AF488 in isolation. Bar = 100 µm. B) d(T)30 FISH in WT myotubes or myotubes overexpressing Ala10 or Al7 PABPN1-TurboID. Red arrows highlight polyadenylated RNA puncta. Gray scale insets show d(T)30-AF488 in isolation. Bar = 100 µm. C) Quantification of Pearson’s correlation showing increased co-localization of DAPI-stained nuclei with d(T)30-AF-488 in myotubes expressing near-native levels of Ala17 PABPN1-TurboID relative to those expressing Ala10 PABPN1-TurboID or WT myotubes. D) Quantification of Pearson’s correlation showing increased co-localization of DAPI-stained nuclei with d(T)30-AF-488 in myotubes over-expressing Ala17 PABPN1-TurboID relative to those over-expressing Ala10 PABPN1-TurboID or to the WT myotubes quantified in C. E) Quantitative PCR of fractionated WT myotubes or those expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID showing increased nuclear localization of the Tnnt3 transcript. For C-E, shown is mean ± standard deviation for n = 6 experiments. Statistical significance determined using one-way ANOVA. * p < 0.05. F) d(T)30-AF-488 FISH showing reduced polyadenylated RNA signal in the cytoplasm of primary myotubes from a knock-in mouse model of OPMD (Pabpn1+/A17, bottom) compared to wild-type litter mates (Pabpn1+/+, top). Gray scale insets show d(T)30-AF488 in isolation. Bar = 50 µm. Shown is one representative image each from three different mice per genotype.
Fig 7 Ala17 PABPN1 causes a dominant negative effect on polyadenylated RNA localization. A) Fluorescence in situ hybridization (FISH) in wild type (WT) myotubes or myotubes expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID using d(T)30-AF-488 to detect polyadenylated RNA and DAPI to stain nuclei. Representative images are shown at low (top) and high (bottom) magnification. Red arrows mark polyadenylated RNA puncta. Gray scale insets show d(T)30-AF488 in isolation. Bar = 100 µm. B) d(T)30 FISH in WT myotubes or myotubes overexpressing Ala10 or Al7 PABPN1-TurboID. Red arrows highlight polyadenylated RNA puncta. Gray scale insets show d(T)30-AF488 in isolation. Bar = 100 µm. C) Quantification of Pearson’s correlation showing increased co-localization of DAPI-stained nuclei with d(T)30-AF-488 in myotubes expressing near-native levels of Ala17 PABPN1-TurboID relative to those expressing Ala10 PABPN1-TurboID or WT myotubes. D) Quantification of Pearson’s correlation showing increased co-localization of DAPI-stained nuclei with d(T)30-AF-488 in myotubes over-expressing Ala17 PABPN1-TurboID relative to those over-expressing Ala10 PABPN1-TurboID or to the WT myotubes quantified in C. E) Quantitative PCR of fractionated WT myotubes or those expressing near-native levels of Ala10 or Ala17 PABPN1-TurboID showing increased nuclear localization of the Tnnt3 transcript. For C-E, shown is mean ± standard deviation for n = 6 experiments. Statistical significance determined using one-way ANOVA. * p < 0.05. F) d(T)30-AF-488 FISH showing reduced polyadenylated RNA signal in the cytoplasm of primary myotubes from a knock-in mouse model of OPMD (Pabpn1+/A17, bottom) compared to wild-type litter mates (Pabpn1+/+, top). Gray scale insets show d(T)30-AF488 in isolation. Bar = 50 µm. Shown is one representative image each from three different mice per genotype.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 48 Not checked · 95 Own results and interpretations

59 more claims

Create a free account to see all 143 claims and to verify the 76 references still open.

See all claims — free account
  • It may state two separate claims as one. 57
  • Probably not a substantial claim. 31
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Research works printed but not linked: 1

  1. Trollet C. Oculopharyngeal Muscular Dystrophy. In: Adam MP, et al. editors. GeneReviews. Seattle, Seattle (WA): University of Washington; 1993.

Cited by

See all 7

Metadata

Authors
Mezzell, A. T., Zhang, Y., Perez, A. M., & Vest, K. E.
Affiliations
University of Cincinnati (US)
Corresponding author
Vest, Katherine E.
Venue
PLOS Genetics
Published
2026-01-26
Volume
22
Issue
1
Pages
e1011743
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W7125712847
Cited by
7
References
53
Citations by year
2026: 7
FWCI
7.88
Type
journal article
Language
en
Open access
Locations
  • PLoS Genetics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Foundation for the National Institutes of Health (R35GM146878)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
oculopharyngeal muscular dystrophy, PABPN1, RNA export, polyadenylation, RNA splicing, dominant negative effect, loss of function, skeletal muscle myotubes, myogenesis, protein-protein interaction, proximity labeling
MeSH terms
Alanine, Animals, Cell Nucleus, Humans, RNA-Binding Proteins, Muscle, Skeletal, Polyadenylation, Poly(A)-Binding Protein I, Muscular Dystrophy, Oculopharyngeal, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.